Table 3.
The HR and 95% CIs calculated by Bayesian network meta-analysis*
| Outcome | Treatment | DFS, HR (95% CI) |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BCS+ALND | BCS+ALND+RT | BCS+ANS+RT | BCS+SLNB | BCS+SLNB+ART+RT | BCS+SLNB+IORT | BCS+SLNB+RT | M | M+ALND | M+ALND+RT | M+RT | ||
| OS, HR (95% CI) | BCS+ALND | — | 1.14 | 1.49 | 1.14 | 1.60 | 1.89 | 1.36 | 1.25 | 1.08 | 1.15 | 0.95 |
| (0.81 to 1.59) | (0.57 to 3.27) | (0.67 to 1.83) | (0.73 to 3.27) | (0.92 to 3.60) | (0.84 to 2.11) | (0.67 to 2.12) | (0.68 to 1.63) | (0.55 to 2.10) | (0.33 to 2.15) | |||
| BCS+ALND+RT | 1.09 | — | 1.31 | 1.01 | 1.40 | 1.67 | 1.20 | 1.11 | 0.97 | 1.01 | 0.84 | |
| (0.91 to 1.30) | (0.54 to 2.71) | (0.62 to 1.58) | (0.70 to 2.69) | (0.85 to 3.04) | (0.80 to 1.73) | (0.62 to 1.81) | (0.57 to 1.53) | (0.53 to 1.69) | (0.30 to 1.86) | |||
| BCS+ANS+RT | 1.93 | 1.77 | — | 0.91 | 1.27 | 1.51 | 1.09 | 1.00 | 0.87 | 0.91 | 0.76 | |
| (0.99 to 3.50) | (0.93 to 3.13) | (0.32 to 2.10) | (0.40 to 3.26) | (0.49 to 3.75) | (0.40 to 2.41) | (0.34 to 2.34) | (0.30 to 1.99) | (0.29 to 2.12) | (0.18 to 2.11) | |||
| BCS+SLNB | 0.89 | 0.82 | 0.51 | — | 1.46 | 1.69 | 1.22 | 1.12 | 1.00 | 1.06 | 0.84 | |
| (0.62 to 1.25) | (0.59 to 1.11) | (0.24 to 0.94) | (0.63 to 3.04) | (0.88 to 3.02) | (0.84 to 1.70) | (0.67 to 1.72 | (0.52 to 1.74) | (0.46 to 2.03) | (0.32 to 1.82) | |||
| BCS+SLNB+ART+RT | 1.18 | 1.08 | 0.67 | 1.35 | — | 1.33 | 0.96 | 0.88 | 0.77 | 0.81 | 0.67 | |
| (0.72 to 1.90) | (0.69 to 1.68) | (0.30 to 1.33) | (0.78 to 2.26) | (0.49 to 2.86) | (0.42 to 1.80) | (0.34 to 1.79) | (0.30 to 1.57) | (0.28 to 1.70) | (0.18 to 1.67) | |||
| BCS+SLNB+IORT | 1.06 | 0.98 | 0.61 | 1.21 | 0.95 | — | 0.77 | 0.71 | 0.64 | 0.67 | 0.54 | |
| (0.64 to 1.67) | (0.60 to 1.51) | (0.26 to 1.19) | (0.77 to 1.79) | (0.48 to 1.66) | (0.44 to 1.22) | (0.34 to 1.27) | (0.27 to 1.24) | (0.25 to 1.41) | (0.17 to 1.23) | |||
| BCS+SLNB+RT | 0.98 | 0.90 | 0.56 | 1.11 | 0.87 | 0.95 | — | 0.92 | 0.83 | 0.87 | 0.70 | |
| (0.72 to 1.31) | (0.69 to 1.154) | (0.27 to 1.01) | (0.90 to 1.34) | (0.51 to 1.37) | (0.64 to 1.36) | (0.59 to 1.37) | (0.45 to 1.41) | (0.40 to 1.62) | (0.70 to 1.48) | |||
| M | 0.98 | 0.90 | 0.56 | 1.11 | 0.88 | 0.96 | 1.00 | — | 0.93 | 0.98 | 0.76 | |
| (0.69 to 1.36) | (0.65 to 1.22) | (0.26 to 1.03) | (0.85 to 1.43) | (0.49 to 1.4) | (0.61 to 1.43) | (0.80 to 1.24) | (0.45 to 1.73) | (0.41 to 1.98) | (0.34 to 1.47) | |||
| M+ALND | 0.83 | 0.77 | 0.48 | 0.97 | 0.75 | 0.83 | 0.87 | 0.87 | — | 1.11 | 0.91 | |
| (0.57 to 1.20) | (0.52 to 1.11) | (0.22 to 0.92) | (0.58 to 1.54) | (0.40 to 1.27) | (0.45 to 1.43) | (0.54 to 1.35) | (0.53 to 1.40) | (0.48 to 2.17) | (0.30 to 2.16) | |||
| M+ALND+RT | 1.16 | 1.07 | 0.67 | 1.35 | 1.04 | 1.16 | 1.21 | 1.22 | 1.45 | — | 0.91 | |
| (0.75 to 1.66) | (0.72 to 1.47) | (0.30 to 1.24) | (0.79 to 2.06) | (0.53 to 1.73) | (0.61 to 1.94) | (0.74 to 1.80) | (0.71 to 1.86) | (0.79 to 2.30) | (0.27 to 2.31) | |||
| M+RT | 0.88 | 0.82 | 0.51 | 1.02 | 0.80 | 0.87 | 0.92 | 0.92 | 1.10 | 0.79 | — | |
| (0.61 to 1.23) | (0.56 to 1.15) | (0.23 to 0.96) | (0.66 to 1.50) | (0.42 to 1.36) | (0.50 to 1.41) | (0.62 to 1.32) | (0.63 to 1.31) | (0.63 to 1.74) | (0.47 to 1.30) | |||
BCS+ALND = breast-conserving surgery+axillary lymph node dissection; BCS+ALND+RT = breast-conserving surgery+axillary lymph node dissection+radiotherapy; BCS+ANS+RT = breast-conserving surgery+axillary node sample+radiotherapy; BCS+SLNB = breast-conserving surgery+sentinel lymph node biopsy; BCS+SLNB+ART+RT = breast-conserving surgery+sentinel lymph node biopsy+axillary radiotherapy+radiotherapy; BCS+SLNB+IORT = breast-conserving surgery+sentinel lymph node biopsy+intraoperative radiotherapy. BCS+SLNB+RT = breast-conserving surgery+sentinel lymph node biopsy+radiotherapy; CI = confidence interval; DFS = disease-free survival; HR = hazard ratio; M = mastectomy; M+ALND = mastectomy+axillary lymph node dissection; M+ALND+RT = mastectomy+axillary lymph node dissection+radiotherapy; M+RT = mastectomy+radiotherapy; OS = overall survival.